Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relationship between several high risk genetic alterations and outcome following IO treatment in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Next Previous
Search
Trial Profile

Relationship between several high risk genetic alterations and outcome following IO treatment in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inotuzumab ozogamicin (Primary)
  • Indications Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 04 Dec 2019 New trial record
    • 06 Nov 2019 Results assessing high risk molecular features associated with response to chemotherapy, response rate and overall prognosis following Inotuzumab ozogamicin, released in the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top